QURE SEC Filing News — uniQure N.V.

Latest SEC filings for uniQure N.V. (QURE) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-09-29.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial t…
Sector: Healthcare Industry: Biotechnology Market Cap: $1.6B
20
Total Filings
0
Bullish Classifications
8
Bearish Classifications
8
Insider Transactions
5
Material Events (8-K)
1
Periodic Reports
Rule-based classifications for QURE currently lean bearish. Of the 20 filing records displayed, 8 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.
QURE Filing Activity Snapshot 2026-06-22 — 2026-09-29
Insider Transactions (Form 4)
0 buys vs 8 sells
Net insider selling in this period — insiders sell for many reasons beyond conviction.
Largest Form 144 Filing
$9.37M
Kapusta Matthew C (Director, CEO, Managing Director) · 2026-06-22
206,100 shares · Form 4
Form 144 Notices
6
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Insider Transactions 8 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 8 filings in this group are Form 4s for uniQure N.V.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 8 insider filings shown, the breakdown is 8 open-market sale. 8 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×8
The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Form 4 Open-market sale Insider Selling 2026-07-07

QURE insider Kapusta Matthew C (Director, CEO, Managing Director) sold 21,082 shares (~$952.1K)

Kapusta Matthew C, listed as Director, CEO, Managing Director at uniQure N.V., reported an open-market sale of 21,082 QURE shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 21,082 $19.39 $408.8K
S Open-market sale 9,200 $44.43 $408.8K
S Open-market sale 4,282 $45.43 $194.5K
S Open-market sale 7,600 $45.89 $348.8K
M Option exercise derivative · Stock Option (Right to Buy) 21,082 — —
Filing: Form 4 (Insider Transaction) Insider: Kapusta Matthew C (Director, CEO, Managing Director) Shares: 21,082 Est. Value: $952.1K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-07-02

QURE insider Abi-Saab Walid (Chief Medical Officer) sold 30,000 shares (~$1.39M)

Abi-Saab Walid, listed as Chief Medical Officer at uniQure N.V., reported an open-market sale of 30,000 QURE shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 10,000 $5.59 $55.9K
S Open-market sale 10,000 $46.46 $464.6K
S Open-market sale 20,000 $46.40 $928.0K
M Option exercise derivative · Stock Option (Right to Buy) 10,000 — —
Filing: Form 4 (Insider Transaction) Insider: Abi-Saab Walid (Chief Medical Officer) Shares: 30,000 Est. Value: $1.39M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-07-02

QURE insider Kaye Jack (Director) sold 21,167 shares (~$983.0K)

Kaye Jack, listed as Director at uniQure N.V., reported an open-market sale of 21,167 QURE shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 4,107 $37.00 $152.0K
S Open-market sale 4,107 $46.49 $190.9K
M Option exercise 17,060 $20.18 $344.3K
S Open-market sale 17,060 $46.43 $792.1K
M Option exercise derivative · Stock Option (Right to Buy) 4,107 — —
M Option exercise derivative · Stock Option (Right to Buy) 17,060 — —
Filing: Form 4 (Insider Transaction) Insider: Kaye Jack (Director) Shares: 21,167 Est. Value: $983.0K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-06-30

QURE insider Abi-Saab Walid (Chief Medical Officer) sold 1,434 shares (~$67.2K)

Abi-Saab Walid, listed as Chief Medical Officer at uniQure N.V., reported an open-market sale of 1,434 QURE shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 1,434 $46.86 $67.2K
Filing: Form 4 (Insider Transaction) Insider: Abi-Saab Walid (Chief Medical Officer) Shares: 1,434 Est. Value: $67.2K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-06-26

QURE insider Kapusta Matthew C (Director, CEO, Managing Director) sold 35,412 shares (~$1.77M)

Kapusta Matthew C, listed as Director, CEO, Managing Director at uniQure N.V., reported an open-market sale of 35,412 QURE shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 4,128 $31.71 $130.9K
S Open-market sale 6,696 $50.00 $334.8K
M Option exercise 28,716 $31.71 $910.6K
S Open-market sale 28,716 $50.02 $1.44M
M Option exercise derivative · Stock Option (Right to Buy) 4,128 — —
M Option exercise derivative · Stock Option (Right to Buy) 28,716 — —
Filing: Form 4 (Insider Transaction) Insider: Kapusta Matthew C (Director, CEO, Managing Director) Shares: 35,412 Est. Value: $1.77M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-06-22

QURE insider Kapusta Matthew C (Director, CEO, Managing Director) sold 206,100 shares (~$9.37M)

Kapusta Matthew C, listed as Director, CEO, Managing Director at uniQure N.V., reported an open-market sale of 206,100 QURE shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 62,581 $19.39 $1.21M
S Open-market sale 23,977 $42.61 $1.02M
S Open-market sale 6,023 $43.70 $263.2K
S Open-market sale 32,581 $45.02 $1.47M
S Open-market sale 56,929 $43.43 $2.47M
S Open-market sale 33,334 $45.01 $1.50M
S Open-market sale 11,585 $48.65 $563.6K
M Option exercise 4,656 $31.71 $147.6K
S Open-market sale 4,656 $50.00 $232.8K
S Open-market sale 37,015 $50.00 $1.85M
M Option exercise derivative · Stock Option (Right to Buy) 62,581 — —
M Option exercise derivative · Stock Option (Right to Buy) 4,656 — —
Filing: Form 4 (Insider Transaction) Insider: Kapusta Matthew C (Director, CEO, Managing Director) Shares: 206,100 Est. Value: $9.37M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-06-22

QURE insider Balachandran Madhavan (Director) sold 11,685 shares (~$526.5K)

Balachandran Madhavan, listed as Director at uniQure N.V., reported an open-market sale of 11,685 QURE shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 5,295 $31.71 $167.9K
M Option exercise 6,390 $19.39 $123.9K
S Open-market sale 5,295 $47.08 $249.3K
S Open-market sale 4,700 $43.66 $205.2K
S Open-market sale 1,690 $42.60 $72.0K
M Option exercise derivative · Stock Option (Right to Buy) 5,295 — —
M Option exercise derivative · Stock Option (Right to Buy) 6,390 — —
Filing: Form 4 (Insider Transaction) Insider: Balachandran Madhavan (Director) Shares: 11,685 Est. Value: $526.5K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-06-22

QURE insider Kaye Jack (Director) sold 5,295 shares (~$225.4K)

Kaye Jack, listed as Director at uniQure N.V., reported an open-market sale of 5,295 QURE shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 5,295 $31.71 $167.9K
S Open-market sale 5,295 $42.57 $225.4K
M Option exercise derivative · Stock Option (Right to Buy) 5,295 — —
Filing: Form 4 (Insider Transaction) Insider: Kaye Jack (Director) Shares: 5,295 Est. Value: $225.4K
View on SEC EDGAR → Open Filing Document →
Proposed Insider Sales 6 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. uniQure N.V. has 6 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-07-02

QURE Form 144 filed for proposed insider sale by Kapusta Matthew C (21,082 shares) ~$951.9K

Kapusta Matthew C filed a Form 144 with the SEC indicating intent to sell QURE (uniQure N.V.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Kapusta Matthew C Shares: 21,082 Est. Value: $951.9K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-06-30

QURE Form 144 filed for proposed insider sale by Abi-Saab Walid (30,000 shares) ~$1.39M

Abi-Saab Walid filed a Form 144 with the SEC indicating intent to sell QURE (uniQure N.V.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Abi-Saab Walid Shares: 30,000 Est. Value: $1.39M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-06-30

QURE Form 144 filed for proposed insider sale by Kaye Jack (21,167 shares) ~$983.0K

Kaye Jack filed a Form 144 with the SEC indicating intent to sell QURE (uniQure N.V.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Kaye Jack Shares: 21,167 Est. Value: $983.0K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-06-26

QURE Form 144 filed for proposed insider sale by Abi-Saab Walid (1,434 shares) ~$67.2K

Abi-Saab Walid filed a Form 144 with the SEC indicating intent to sell QURE (uniQure N.V.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Abi-Saab Walid Shares: 1,434 Est. Value: $67.2K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-06-25

QURE Form 144 filed for proposed insider sale by Kapusta Matthew C (28,716 shares) ~$1.44M

Kapusta Matthew C filed a Form 144 with the SEC indicating intent to sell QURE (uniQure N.V.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Kapusta Matthew C Shares: 28,716 Est. Value: $1.44M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-06-24

QURE Form 144 filed for proposed insider sale by Kapusta Matthew C (6,696 shares) ~$334.8K

Kapusta Matthew C filed a Form 144 with the SEC indicating intent to sell QURE (uniQure N.V.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Kapusta Matthew C Shares: 6,696 Est. Value: $334.8K
View on SEC EDGAR → Open Filing Document →
Material Events 5 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 5 in this period for uniQure N.V. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-09-29

QURE filed 8-K — material company event

uniQure N.V. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-09-02

QURE filed 8-K — material company event

uniQure N.V. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-07-29

QURE filed 8-K — material company event

uniQure N.V. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-06-24

QURE filed 8-K — material company event

uniQure N.V. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-06-22

QURE filed 8-K — material company event

uniQure N.V. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for uniQure N.V.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-07-29

QURE filed Quarterly Report (10-Q)

uniQure N.V. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →

How we classify uniQure N.V.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on QURE. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — QURE SEC Filings

More Tools for QURE

QURE Full Stock Analysis QURE Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper QURE analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the QURE stock analysis page.

QURE Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer